272 related articles for article (PubMed ID: 33533182)
1. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
2. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
3. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
Roth KG; Mambetsariev I; Salgia R
Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33335011
[TBL] [Abstract][Full Text] [Related]
5. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation.
Tanaka H; Taima K; Makiguchi T; Nakagawa J; Niioka T; Tasaka S
Cancer Commun (Lond); 2021 Jan; 41(1):83-87. PubMed ID: 33387444
[TBL] [Abstract][Full Text] [Related]
6. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
8. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Morise M; Kato T; Matsumoto S; Inoue T; Sakamoto T; Tokito T; Atagi S; Kozuki T; Takeoka H; Chikamori K; Shinagawa N; Tanaka H; Horii E; Adrian S; Bruns R; Johne A; Paik PK; Sakai H
Cancer Sci; 2024 Apr; 115(4):1296-1305. PubMed ID: 38402853
[TBL] [Abstract][Full Text] [Related]
9. Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.
Takamori S; Seto T; Yamaguchi M; Kinoshita F; Fujishita T; Ito K; Toyozawa R; Shoji F; Okamoto T
Front Oncol; 2022; 12():965741. PubMed ID: 36313664
[TBL] [Abstract][Full Text] [Related]
10. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
[TBL] [Abstract][Full Text] [Related]
11. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
13. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
[TBL] [Abstract][Full Text] [Related]
14. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
15. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Friese-Hamim M; Clark A; Perrin D; Crowley L; Reusch C; Bogatyrova O; Zhang H; Crandall T; Lin J; Ma J; Bachner D; Schmidt J; Schaefer M; Stroh C
Lung Cancer; 2022 Jan; 163():77-86. PubMed ID: 34942492
[TBL] [Abstract][Full Text] [Related]
16. Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.
Kunimasa K; Kawamura T; Tamiya M; Inoue T; Kuhara H; Nishino K; Kumagai T
Thorac Cancer; 2021 Dec; 12(24):3426-3428. PubMed ID: 34695875
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Shitara K; Yamazaki K; Tsushima T; Naito T; Matsubara N; Watanabe M; Sarholz B; Johne A; Doi T
Jpn J Clin Oncol; 2020 Aug; 50(8):859-866. PubMed ID: 32328660
[TBL] [Abstract][Full Text] [Related]
18. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W; Hietala SF; Nyberg J; Papasouliotis O; Johne A; Berghoff K; Goteti K; Dong J; Girard P; Venkatakrishnan K; Strotmann R
Cancer Chemother Pharmacol; 2022 Jul; 90(1):53-69. PubMed ID: 35771259
[TBL] [Abstract][Full Text] [Related]
19. INSIGHT 2: a phase II study of tepotinib plus osimertinib in
F Smit E; Dooms C; Raskin J; Nadal E; Tho LM; Le X; Mazieres J; S Hin H; Morise M; W Zhu V; Tan D; H Holmberg K; Ellers-Lenz B; Adrian S; Brutlach S; Schumacher KM; Karachaliou N; Wu YL
Future Oncol; 2022 Mar; 18(9):1039-1054. PubMed ID: 34918545
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
